iX Biopharma Ltd. (SGX:42C)
Singapore · Delayed Price · Currency is SGD 0.3300
-0.0150 (-4.35%)
Jun 10, 2026, 5:09 PM SGT
iX Biopharma Income Statement
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Revenue | 7 | 7.77 | 5.96 | 5.91 | 14.39 | 1.75 |
Revenue Growth (YoY) | -5.18% | 30.34% | 0.78% | -58.91% | 724.64% | 77.16% |
Cost of Revenue | 4.87 | 5.73 | 4.91 | 3.59 | 2.1 | 2.13 |
Gross Profit | 2.14 | 2.04 | 1.05 | 2.32 | 12.29 | -0.38 |
Selling, General & Admin | 6.51 | 6.69 | 6.71 | 9.04 | 9.46 | 8.3 |
Research & Development | 1.57 | 1.64 | 1.73 | 2.82 | 2.33 | 2.75 |
Operating Expenses | 8.11 | 8.33 | 8.54 | 11.86 | 11.79 | 11.05 |
Operating Income | -5.97 | -6.29 | -7.5 | -9.54 | 0.5 | -11.43 |
Interest Expense | -0.68 | -0.33 | -0.44 | -0.27 | -0.2 | -0.17 |
Interest & Investment Income | 0.02 | 0.02 | 0.03 | 0.01 | - | 0.01 |
Currency Exchange Gain (Loss) | -3.4 | -3.4 | 0.08 | -2.77 | -1.91 | 1.8 |
Other Non Operating Income (Expenses) | 5.37 | -0.14 | 0.35 | 1.12 | 0.74 | 1.57 |
EBT Excluding Unusual Items | -4.66 | -10.14 | -7.47 | -11.46 | -0.88 | -8.23 |
Gain (Loss) on Sale of Investments | -0.01 | -0.01 | -2.51 | 1.74 | -3.26 | - |
Other Unusual Items | - | - | - | 0.01 | 0.04 | - |
Pretax Income | -4.67 | -10.14 | -9.99 | -9.71 | -4.1 | -8.23 |
Income Tax Expense | 0 | 0 | 0.81 | -0.09 | 0.5 | 0 |
Earnings From Continuing Operations | -4.67 | -10.14 | -10.79 | -9.62 | -4.6 | -8.23 |
Net Income | -4.67 | -10.14 | -10.79 | -9.62 | -4.6 | -8.23 |
Net Income to Common | -4.67 | -10.14 | -10.79 | -9.62 | -4.6 | -8.23 |
Shares Outstanding (Basic) | 914 | 877 | 767 | 765 | 746 | 693 |
Shares Outstanding (Diluted) | 914 | 877 | 767 | 765 | 746 | 693 |
Shares Change (YoY) | 7.68% | 14.25% | 0.33% | 2.51% | 7.60% | 7.13% |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Free Cash Flow | -5.8 | -3.96 | -6.83 | -8.36 | 2.92 | -8.91 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
Gross Margin | 30.51% | 26.27% | 17.59% | 39.24% | 85.41% | -21.89% |
Operating Margin | -85.30% | -80.92% | -125.78% | -161.41% | 3.48% | -654.96% |
Profit Margin | -66.70% | -130.56% | -181.14% | -162.61% | -31.95% | -471.86% |
Free Cash Flow Margin | -82.80% | -50.97% | -114.57% | -141.30% | 20.31% | -510.32% |
EBITDA | -5.68 | -5.87 | -7.08 | -9.04 | 1.15 | -10.79 |
EBITDA Margin | -81.07% | -75.59% | -118.88% | -152.93% | 7.99% | - |
D&A For EBITDA | 0.3 | 0.41 | 0.41 | 0.5 | 0.65 | 0.64 |
EBIT | -5.97 | -6.29 | -7.5 | -9.54 | 0.5 | -11.43 |
EBIT Margin | -85.30% | -80.92% | -125.78% | -161.41% | 3.48% | - |